Pharmacological strategies such as utilization of GLP-1 receptor agonists, SGLT-2 inhibitors, statins, and thiazolidinediones have shown promise in simultaneously addressing hepatic steatosis and reducing AF burden. This evidence concerns the gene SLC5A2 and fatty liver disease.